Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 407

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 407
---
 on 14 June 2023, the share capital of the Company consists of an unlimited number of ordinary
shares of nominal value £0.001 each. Ordinary and deferred shares were recorded as equity.

Rights attaching
to the shares following the incorporation of Biodexa Pharmaceuticals plc

Shares classified
as equity

The holders of ordinary
shares in the capital of the Company have the following rights:

(a) to receive
notice of, to attend and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share
of which he is the holder; and,

(b) to receive
such dividend as is declared by the Board on each share held.

The holders of both
classes of deferred shares in the capital of the Company:

(a) shall not
be entitled to receive notice of or to attend or speak at any general meeting of the Company or to vote on any resolution to be proposed
at any general meeting of the Company; and

(b) shall not
be entitled to receive any dividend or other distribution of out of the profits of the Company.

In the event of a distribution
of assets, the deferred shareholders shall receive the nominal amount paid up on such share after the holder of each ordinary share shall
have received (in cash or specie) the amount paid up or credited as paid up on such ordinary share together with an additional payment
of £100 per share. The Company has the authority to purchase the deferred shares and may require the holder of the deferred shares
to sell them for a price not exceeding 1p for all the deferred shares.

| F-69 |

| 21 | Share capital (continued) |

| Schedule of ordinary and deferred shares |     |                                |     |                        |     |               |     |               |     |         |     |                           |
|                                          |     |                                |     | Ordinary Shares Number |     |  ‘A’ Deferred 
 Shares Number |     |  ‘B’ Deferred 
 Shares Number |     |   Share 
 Price £ |     | Total consideration £’000 |
| At 1 January 2021                        |     |                                |     |              3,153,694 |     |     1,000,001 |     |               |     |         |     |                           |
| 19 February 2021                         |     | Exercise                       
 of warrants                    |     |                 15,340 |     |               |     |               |     |   5.960 |